Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Real-time Estimate Cboe BZX Other stock markets 02:25:13 2024-05-13 pm EDT			5-day change	1st Jan Change
43.16 ^USD	-0.19%		-4.33%	-28.04%

03:32pm	Sector Update: Health Care Stocks Decline Pre-Bell Monday	MT
03:11pm	Sector Update: Health Care	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	Apr. 17	MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	Apr. 03	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	Mar. 18	MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	Mar. 13	MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	Jan. 03	MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target	Dec. 19	MT
Earnings, Interest Rates Cap Wall Street Pre-Bell; Asia Choppy, Europe Up	Nov. 20	MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating	Nov. 15	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating	23-07-21	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating	23-07-21	MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating	23-07-20	MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating	23-06-13	MT
HC Wainwright Adjusts Legend Biotech Price Target to $82 From $77, Maintains Buy Rating	23-06-06	MT
William Blair Initiates Legend Biotech at Market Perform	23-05-25	MT
Daiwa Securities Initiates Legend Biotech at Buy Rating	23-05-22	MT
Barclays Adjusts Price Target on Legend Biotech to $90 From $65, Keeps Overweight Rating	23-05-19	MT
RBC Boosts Price Target on Legend Biotech to $83 From $74, Cites Greater Confidence in Manufacturing Progress, Keeps Outperform Rating	23-05-19	MT
BMO Capital Adjusts Price Target on Legend Biotech to $90 From $79, Maintains Outperform Rating	23-04-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Legend Biotech Corporation

Equities

LEGN

US52490G1022

Analyst Reco.

Filters